Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07585760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

Study acronym: CAREMM-012
StatusRecruiting
PhasePhase 2
Started2026-09-10
View on ClinicalTrials.gov ↗

Amendment history

2026-06-30
Study Identification, Study Status, Study Description, Conditions, Study Design, Outcome Measures, Eligibility v1
Enrollment increased: 20 → 26 participants
Start date2026-05-15→2026-07-25
Eligibility criteriarevised
[...] defined as an estimated glomerular filtration rate (eGFR) < 3040 mL/min (calculated using the Modification of Diet in Renal [...]
Secondary endpoints6 to 7 entries
Rate of Renal Partial Response or Better
Study title-7 characters
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment
2026-05-10
Original filing
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment (\[eGFR\] \< 40 mL/min). Enrolled subjects will receive three consecutive cycles of induction therapy with CM336 in combination with isatuximab.
Trial Details
NCT Number NCT07585760
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
Enrollment 26 participants
Start Date 2026-09-10
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-17